Leukemia inhibitory factor suppresses hepatic de novo lipogenesis and induces cachexia in mice

Nat Commun. 2024 Jan 20;15(1):627. doi: 10.1038/s41467-024-44924-w.

Abstract

Cancer cachexia is a systemic metabolic syndrome characterized by involuntary weight loss, and muscle and adipose tissue wasting. Mechanisms underlying cachexia remain poorly understood. Leukemia inhibitory factor (LIF), a multi-functional cytokine, has been suggested as a cachexia-inducing factor. In a transgenic mouse model with conditional LIF expression, systemic elevation of LIF induces cachexia. LIF overexpression decreases de novo lipogenesis and disrupts lipid homeostasis in the liver. Liver-specific LIF receptor knockout attenuates LIF-induced cachexia, suggesting that LIF-induced functional changes in the liver contribute to cachexia. Mechanistically, LIF overexpression activates STAT3 to downregulate PPARα, a master regulator of lipid metabolism, leading to the downregulation of a group of PPARα target genes involved in lipogenesis and decreased lipogenesis in the liver. Activating PPARα by fenofibrate, a PPARα agonist, restores lipid homeostasis in the liver and inhibits LIF-induced cachexia. These results provide valuable insights into cachexia, which may help develop strategies to treat cancer cachexia.

MeSH terms

  • Animals
  • Cachexia* / genetics
  • Cachexia* / metabolism
  • Leukemia Inhibitory Factor / genetics
  • Leukemia Inhibitory Factor / metabolism
  • Lipids
  • Lipogenesis / genetics
  • Liver / metabolism
  • Mice
  • Mice, Transgenic
  • Neoplasms* / metabolism
  • PPAR alpha / genetics
  • PPAR alpha / metabolism

Substances

  • Leukemia Inhibitory Factor
  • Lipids
  • PPAR alpha
  • Lif protein, mouse